Investors Buy Large Volume of GlycoMimetics Put Options (NASDAQ:GLYC)

GlycoMimetics, Inc. (NASDAQ:GLYC) was the target of some unusual options trading activity on Monday. Investors acquired 14,196 put options on the stock. This is an increase of approximately 830% compared to the average volume of 1,526 put options.

Analysts Set New Price Targets

Several brokerages recently issued reports on GLYC. Capital One Financial reiterated an “overweight” rating on shares of GlycoMimetics in a report on Thursday, February 22nd. StockNews.com lowered shares of GlycoMimetics from a “hold” rating to a “sell” rating in a research report on Thursday, March 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of GlycoMimetics in a research report on Wednesday, March 27th.

Institutional Investors Weigh In On GlycoMimetics

Several institutional investors have recently added to or reduced their stakes in the business. Acuta Capital Partners LLC purchased a new position in shares of GlycoMimetics in the third quarter valued at $41,000. Advisor OS LLC purchased a new position in GlycoMimetics during the 4th quarter valued at about $238,000. Finally, MJP Associates Inc. ADV purchased a new position in GlycoMimetics during the 4th quarter valued at about $238,000. 75.19% of the stock is owned by hedge funds and other institutional investors.

GlycoMimetics Price Performance

Shares of NASDAQ:GLYC traded down $1.47 during midday trading on Monday, reaching $0.37. The company had a trading volume of 32,181,239 shares, compared to its average volume of 850,503. The company’s 50 day moving average price is $2.53 and its 200 day moving average price is $2.35. GlycoMimetics has a 52-week low of $0.34 and a 52-week high of $3.53.

GlycoMimetics (NASDAQ:GLYC) last issued its earnings results on Wednesday, March 27th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. The firm had revenue of $0.01 million during the quarter. On average, equities research analysts forecast that GlycoMimetics will post -0.54 earnings per share for the current year.

About GlycoMimetics

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.